Parodi Maurizio Battaglia, Di Crecchio Lorenzo
Eye Clinic, University of Trieste, Italy.
Semin Ophthalmol. 2003 Sep;18(3):154-9. doi: 10.1076/soph.18.3.154.29809.
Several investigators have tried to assess the role of hyperhomocysteinemia and the 677C-T mutation in the methylenetetrahydrofolate reductase (MTHFR) gene as risk factors in retinal vein occlusion with contrasting results. Aim of the study is to investigate the correlation between increased homocysteine plasma level and the homozygosity for the 677C-T mutation in the gene MTHFR in patients aged under 50 years affected by central retinal vein occlusion (CRVO).
Through a prospective, case-control study, 31 patients under 50 years of age and diagnosed with CRVO were compared with two control groups. The first control group (GROUP I) included 31 subjects matched for age, sex, laboratory tests and the main risk factors for atherosclerosis. The second control group (GROUP II) consisted of 31 volunteers matched only for age and sex.
The mean homocysteine plasma level was 10.60 micromol/l in patients, 10.39 micromol/l in GROUP I and 9.34 micromol/l in GROUP II. There was no statistically significant difference between mean homocysteine plasma level in cases and in GROUP I. Mean homocysteine plasma level was lower in GROUP II than in patients, and the difference was statistically significant. Homozygosity for the 677C-T mutation in the MTHFR was found in four patients (12.9%), in five controls in GROUP I (16.1%) and in four controls in GROUP II (12.9%).
Our results support first of all the hypothesis that the homocysteine plasma level is not a primary and independent risk factor for central retinal vein occlusion, but is more likely a marker of atherosclerosis and the consequence of other well-established risk factors. Second, the importance of the design of the study is highlighted, since the obtained results differed on the basis of the considered control group. This feature could contribute to explain the contradictory results previously reported in the literature.
几位研究者试图评估高同型半胱氨酸血症及亚甲基四氢叶酸还原酶(MTHFR)基因677C-T突变作为视网膜静脉阻塞危险因素的作用,结果却相互矛盾。本研究旨在调查年龄在50岁以下的中心性视网膜静脉阻塞(CRVO)患者血浆同型半胱氨酸水平升高与MTHFR基因677C-T突变纯合性之间的相关性。
通过一项前瞻性病例对照研究,将31例年龄在50岁以下且诊断为CRVO的患者与两个对照组进行比较。第一个对照组(第一组)包括31名在年龄、性别、实验室检查及动脉粥样硬化主要危险因素方面相匹配的受试者。第二个对照组(第二组)由31名仅在年龄和性别方面相匹配的志愿者组成。
患者的平均血浆同型半胱氨酸水平为10.60微摩尔/升,第一组为10.39微摩尔/升,第二组为9.34微摩尔/升。病例组与第一组的平均血浆同型半胱氨酸水平之间无统计学显著差异。第二组的平均血浆同型半胱氨酸水平低于患者组,差异具有统计学显著性。在4例患者(12.9%)、第一组的5名对照组受试者(16.1%)和第二组的4名对照组受试者(12.9%)中发现了MTHFR基因677C-T突变纯合性。
我们的结果首先支持以下假设,即血浆同型半胱氨酸水平不是中心性视网膜静脉阻塞的主要和独立危险因素,而更可能是动脉粥样硬化的标志物以及其他已明确危险因素的结果。其次,强调了研究设计的重要性,因为根据所考虑的对照组不同,所得结果也不同。这一特征可能有助于解释先前文献中报道的相互矛盾的结果。